Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

2.

Can Prior Authorization Be Better With Artificial Intelligence?

3.

De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer

4.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

5.

Having a tattoo could increase your risk of developing lymphoma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot